|
USRE42190E1
(en)
|
1998-11-20 |
2011-03-01 |
Arena Pharmaceuticals, Inc. |
Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
|
|
US7816492B2
(en)
*
|
1998-11-20 |
2010-10-19 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors
|
|
ATE301673T1
(de)
*
|
1998-11-20 |
2005-08-15 |
Arena Pharm Inc |
Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand
|
|
US20030017528A1
(en)
*
|
1998-11-20 |
2003-01-23 |
Ruoping Chen |
Human orphan G protein-coupled receptors
|
|
US20030125539A1
(en)
*
|
1999-02-22 |
2003-07-03 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
|
US6221660B1
(en)
|
1999-02-22 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
|
AU5168700A
(en)
*
|
1999-05-28 |
2000-12-18 |
Synaptic Pharmaceutical Corporation |
Dna encoding snorf33 receptor
|
|
GB9923177D0
(en)
*
|
1999-09-30 |
1999-12-01 |
Pfizer Ltd |
Novel polypeptide
|
|
EP1226250A2
(en)
*
|
1999-11-03 |
2002-07-31 |
MERCK PATENT GmbH |
Gpcr-kd5 polypeptides and dna sequences thereof
|
|
CA2388865A1
(en)
*
|
1999-11-16 |
2001-05-25 |
Pharmacia & Upjohn Company |
Novel g protein-coupled receptors
|
|
EP1287133B1
(en)
*
|
2000-05-18 |
2006-12-13 |
Bayer HealthCare AG |
Regulation of human dopamine-like g protein-coupled receptor
|
|
EP1770159A1
(en)
*
|
2000-12-01 |
2007-04-04 |
Astellas Pharma Inc. |
Process for manufacturing a pharmaceutical composition for treating diabetes
|
|
US20030064381A1
(en)
*
|
2001-03-07 |
2003-04-03 |
Feder John N. |
Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY26, expressed highly in testis and gastrointestinal tissues
|
|
US20030045685A1
(en)
*
|
2001-03-09 |
2003-03-06 |
Tularik Inc. |
Novel receptors
|
|
US7053121B2
(en)
*
|
2001-03-19 |
2006-05-30 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating circadian rhythms
|
|
EP2272946B9
(en)
|
2002-02-25 |
2015-06-24 |
Vaxiion Therapeutics, LLC |
Minicell compositions and methods
|
|
EP1538217A4
(en)
*
|
2002-09-11 |
2006-09-27 |
Astellas Pharma Inc |
SCREENING METHOD FOR INSULATION STOP ENHANCER
|
|
US20030143590A1
(en)
*
|
2002-11-18 |
2003-07-31 |
Shyam Ramakrishnan |
Regulation of human dopamine-like g protein- coupled receptor
|
|
US20080009551A1
(en)
*
|
2003-04-30 |
2008-01-10 |
Arena Pharmaceuticals, Inc. |
Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
|
|
US7083933B1
(en)
*
|
2003-05-09 |
2006-08-01 |
Prosidion Limited |
Methods for identification of modulators of OSGPR116 activity
|
|
EP1625159B1
(en)
*
|
2003-05-20 |
2011-03-02 |
The University Court Of The University Of Glasgow |
Materials and methods relating to g-protein coupled receptor oligomers
|
|
US7309589B2
(en)
*
|
2004-08-20 |
2007-12-18 |
Vironix Llc |
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
|
|
KR20070091038A
(ko)
*
|
2004-12-24 |
2007-09-06 |
프로시디온 리미티드 |
Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
|
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
US7306203B2
(en)
*
|
2005-01-28 |
2007-12-11 |
Platt Robert E |
Post assembly and spacer for use therewith
|
|
WO2006113236A2
(en)
*
|
2005-04-14 |
2006-10-26 |
Cornell Research Foundation, Inc. |
Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway
|
|
AU2006264649A1
(en)
*
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
GPCR agonists
|
|
US20090325924A1
(en)
*
|
2005-06-30 |
2009-12-31 |
Stuart Edward |
GPCR Agonists
|
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
NZ571110A
(en)
*
|
2006-04-11 |
2011-03-31 |
Arena Pharm Inc |
Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
|
|
US7638541B2
(en)
*
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
|
CL2008000018A1
(es)
|
2007-01-04 |
2008-08-01 |
Prosidion Ltd |
Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
|
|
EP2114933B1
(en)
|
2007-01-04 |
2011-09-07 |
Prosidion Ltd |
Piperidine gpcr agonists
|
|
EA016507B1
(ru)
*
|
2007-01-04 |
2012-05-30 |
Прозидион Лимитед |
Пиперидиновые агонисты gpcr
|
|
PE20081849A1
(es)
*
|
2007-01-04 |
2009-01-26 |
Prosidion Ltd |
Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
|
|
AU2008279447A1
(en)
*
|
2007-07-19 |
2009-01-29 |
Metabolex, Inc. |
N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
|
|
JP2010539152A
(ja)
*
|
2007-09-10 |
2010-12-16 |
プロシディオン・リミテッド |
代謝障害の治療のための化合物
|
|
ES2499018T3
(es)
*
|
2007-09-20 |
2014-09-26 |
Irm Llc |
Compuestos y composiciones como moduladores de la actividad de GPR119
|
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
|
PL2280704T3
(pl)
*
|
2008-03-31 |
2015-10-30 |
Cymabay Therapeutics Inc |
Związki oksymetylenoarylowe i ich zastosowania
|
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
GB0812649D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
GB0812642D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
ATE557024T1
(de)
*
|
2008-07-10 |
2012-05-15 |
Prosidion Ltd |
Piperidinverbindungen als gpcr-agonisten
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
ES2403120T3
(es)
|
2008-12-24 |
2013-05-14 |
Cadila Healthcare Limited |
Nuevos derivados de oxima
|
|
GB0904284D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB0904285D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB0904287D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
WO2010118404A2
(en)
*
|
2009-04-09 |
2010-10-14 |
California Institute Of Technology |
Methods for creating or identifying compounds that bind tumor necrosis factor alpha
|
|
KR101432396B1
(ko)
|
2009-06-18 |
2014-08-20 |
카딜라 핼쓰캐어 리미티드 |
신규한 ｇｐｒ 119 작용물질
|
|
US8293729B2
(en)
*
|
2009-06-24 |
2012-10-23 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical composition and methods relating thereto
|
|
US8481731B2
(en)
*
|
2009-06-24 |
2013-07-09 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical composition and methods relating thereto
|
|
JP2012228180A
(ja)
*
|
2009-09-02 |
2012-11-22 |
Panasonic Corp |
脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
|
|
JP2012228181A
(ja)
*
|
2009-09-02 |
2012-11-22 |
Panasonic Corp |
脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
|
|
EP2483281B1
(en)
|
2009-10-01 |
2014-06-04 |
Cymabay Therapeutics, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
|
GB201006167D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB201006166D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
BR112012032248A2
(pt)
|
2010-06-23 |
2016-09-13 |
Metabolex Inc |
composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
SG188547A1
(en)
|
2010-10-08 |
2013-04-30 |
Cadila Healthcare Ltd |
Novel gpr 119 agonists
|
|
GB201114389D0
(en)
|
2011-08-22 |
2011-10-05 |
Prosidion Ltd |
Novel compounds
|
|
AR083904A1
(es)
|
2010-11-18 |
2013-04-10 |
Prosidion Ltd |
Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
|
|
KR101913619B1
(ko)
|
2011-06-09 |
2018-12-28 |
리젠 파마슈티컬스 소시에떼 아노님 |
Gpr-119의 조절제로서의 신규한 화합물
|
|
WO2018026890A1
(en)
|
2016-08-03 |
2018-02-08 |
Cymabay Therapeutics |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|